COVID-19 vaccines in multiple sclerosis treated with cladribine or ocrelizumab

Since the recent approval of vaccines against COVID-19, efficacy concerns emerged for MS patients treated with immunosuppressive drugs. We report our experience in four patients, under cladribine (two) or under ocrelizumab (two) treatment, all with low lymphocyte count, three of them vaccinated afte...

Descripción completa

Detalles Bibliográficos
Autores principales: Buttari, Fabio, Bruno, Antonio, Dolcetti, Ettore, Azzolini, Federica, Bellantonio, Paolo, Centonze, Diego, Fantozzi, Roberta
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier B.V. 2021
Materias:
Correspondence
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8093161/
https://www.ncbi.nlm.nih.gov/pubmed/33990054
http://dx.doi.org/10.1016/j.msard.2021.102983
_version_ 1783687757545078784
author Buttari, Fabio
Bruno, Antonio
Dolcetti, Ettore
Azzolini, Federica
Bellantonio, Paolo
Centonze, Diego
Fantozzi, Roberta
author_facet Buttari, Fabio
Bruno, Antonio
Dolcetti, Ettore
Azzolini, Federica
Bellantonio, Paolo
Centonze, Diego
Fantozzi, Roberta
author_sort Buttari, Fabio
collection PubMed
description Since the recent approval of vaccines against COVID-19, efficacy concerns emerged for MS patients treated with immunosuppressive drugs. We report our experience in four patients, under cladribine (two) or under ocrelizumab (two) treatment, all with low lymphocyte count, three of them vaccinated after 3 months from the last dose with good immune response, one (under ocrelizumab) after 2 months, without developing an appropriate title of antibodies. This experience suggests that the discriminant for the response to the vaccine is not the lymphocyte count but the timing of the vaccination.
format Online
Article
Text
id pubmed-8093161
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Elsevier B.V.
record_format MEDLINE/PubMed
spelling pubmed-80931612021-05-05 COVID-19 vaccines in multiple sclerosis treated with cladribine or ocrelizumab Buttari, Fabio Bruno, Antonio Dolcetti, Ettore Azzolini, Federica Bellantonio, Paolo Centonze, Diego Fantozzi, Roberta Mult Scler Relat Disord Correspondence Since the recent approval of vaccines against COVID-19, efficacy concerns emerged for MS patients treated with immunosuppressive drugs. We report our experience in four patients, under cladribine (two) or under ocrelizumab (two) treatment, all with low lymphocyte count, three of them vaccinated after 3 months from the last dose with good immune response, one (under ocrelizumab) after 2 months, without developing an appropriate title of antibodies. This experience suggests that the discriminant for the response to the vaccine is not the lymphocyte count but the timing of the vaccination. Elsevier B.V. 2021-07 2021-05-04 /pmc/articles/PMC8093161/ /pubmed/33990054 http://dx.doi.org/10.1016/j.msard.2021.102983 Text en © 2021 Elsevier B.V. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Correspondence
Buttari, Fabio
Bruno, Antonio
Dolcetti, Ettore
Azzolini, Federica
Bellantonio, Paolo
Centonze, Diego
Fantozzi, Roberta
COVID-19 vaccines in multiple sclerosis treated with cladribine or ocrelizumab
title COVID-19 vaccines in multiple sclerosis treated with cladribine or ocrelizumab
title_full COVID-19 vaccines in multiple sclerosis treated with cladribine or ocrelizumab
title_fullStr COVID-19 vaccines in multiple sclerosis treated with cladribine or ocrelizumab
title_full_unstemmed COVID-19 vaccines in multiple sclerosis treated with cladribine or ocrelizumab
title_short COVID-19 vaccines in multiple sclerosis treated with cladribine or ocrelizumab
title_sort covid-19 vaccines in multiple sclerosis treated with cladribine or ocrelizumab
topic Correspondence
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8093161/
https://www.ncbi.nlm.nih.gov/pubmed/33990054
http://dx.doi.org/10.1016/j.msard.2021.102983
work_keys_str_mv AT buttarifabio covid19vaccinesinmultiplesclerosistreatedwithcladribineorocrelizumab
AT brunoantonio covid19vaccinesinmultiplesclerosistreatedwithcladribineorocrelizumab
AT dolcettiettore covid19vaccinesinmultiplesclerosistreatedwithcladribineorocrelizumab
AT azzolinifederica covid19vaccinesinmultiplesclerosistreatedwithcladribineorocrelizumab
AT bellantoniopaolo covid19vaccinesinmultiplesclerosistreatedwithcladribineorocrelizumab
AT centonzediego covid19vaccinesinmultiplesclerosistreatedwithcladribineorocrelizumab
AT fantozziroberta covid19vaccinesinmultiplesclerosistreatedwithcladribineorocrelizumab

Ejemplares similares